Director/PDMR Shareholding
24 February 2023 11:00 GMT
Transaction by Person Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announces that, on 22 February 2023, it was notified by Aradhana Sarin, Executive Director and Chief Financial Officer, that, on 17 February 2023 , Dr Sarin ceased to be beneficially interested in 200 American Depositary Shares (ADSs) of the Company, following the gift of those shares to charity for nil consideration. Each ADS represents one half of an ordinary share of $0.25 each in the Company.
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Aradhana Sarin |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer |
||||
|
b)
|
Initial notification/Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code |
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
||||
|
b)
|
Nature of the transaction
|
Gift of shares to charity for nil consideration |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price |
Not applicable - single transaction
|
||||
|
e)
|
Date of the transaction
|
17 February 2023 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 23 minutes ago River Global Plc
- 1 hour ago Pipehawk
- 1 hour ago Frasers Group
- 1 hour ago DP Aircraft I Limited Pref
- 1 hour ago Cropper (James)